Wall Street expects a year-over-year increase in earnings on higher revenues when Arcutis Biotherapeutics, Inc. (ARQT) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2025, might help the stock move higher if these key numbers are be ...

Core Insights - The article discusses potential investment opportunities in ARQT, indicating a possible long position in the stock within the next 72 hours [1]. Group 1 - The analyst has no current stock or derivative positions in the companies mentioned but may initiate a beneficial long position [1]. - The article expresses the author's own opinions and is not influenced by compensation from any company [1]. - There is no business relationship with any company whose stock is mentioned in the article [1].

WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the pres ...

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, Arcutis' chief financial officer (CFO) is retiring from the Company and Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team as part of a planned succession. Mr. Topper will continue to serve as CFO ...

Arcutis Biotherapeutics, Inc. (ARQT) shares soared 10.8% in the last trading session to close at $16.60. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.8% gain over the past four weeks.The stock rallied after the company announced that Padagis had requested a stay to the ongoing patent litigation between Padagis and Arcutis. The companies agreed to stay the patent lawsuit related to Arcutis’ patented product Zoryve (roflumila ...

WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the ...

Group 1 - Arcutis Biotherapeutics, Inc. (ARQT) shares have increased by 25.7% over the past four weeks, closing at $16.09, with a mean price target of $20.25 indicating a potential upside of 25.9% [1] - The average price targets from analysts range from a low of $15 to a high of $29, with a standard deviation of $3.96, suggesting variability in estimates [2] - Analysts show a consensus that ARQT will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][10] Group 2 - The Zacks Consensus Estimate for ARQT has increased by 50.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [11] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [12]

Core Insights - Arcutis Biotherapeutics, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference from April 7–10, 2025, with a fireside chat scheduled for April 8, 2025, at 11:00 am EDT [1] - The company focuses on developing innovations in immuno-dermatology, addressing the needs of patients with immune-mediated dermatological diseases [2] Company Overview - Arcutis is a commercial-stage medical dermatology company with a commitment to addressing persistent patient challenges in dermatology [2] - The company has a growing portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down ...

Shares of Arcutis Biotherapeutics, Inc. (ARQT) have gained 2.3% over the past four weeks to close the last trading session at $13.40, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $19.88 indicates a potential upside of 48.4%.The average comprises eight short-term price targets ranging from a low of $15 to a high of $29, with a standard deviation of $4.22. While the lowest esti ...